HU-6 is under clinical development by Rivus Pharmaceuticals and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II drugs for Hypertriglyceridemia have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HU-6’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HU-6 overview

HU-6 is under development for the treatment of non-alcoholic steatohepatitis (NASH), non alcoholic fatty liver disease (NAFLD), type 2 diabetes, severe hypertriglyceridemia (SHTG) and heart failure with preserved ejection fraction (HFpEF). It is administered through oral route. It acts by targeting adenine nucleotide translocase (ANT).

Rivus Pharmaceuticals overview

Rivus Pharmaceuticals is a developer of controlled metabolic accelerators that providing patients with oral small molecule therapeutics which address the underlying metabolic risk factors. The company is headquartered in Charlottesville, Virginia, the US.

For a complete picture of HU-6’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.